← Back to Search

Cardiac Glycoside

Digoxin 3 mcg/Kg/day for Inflammation

Phase 1
Waitlist Available
Led By Wajahat Mehal, MD
Research Sponsored by Yale University
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 6 weeks
Awards & highlights

Study Summary

This trial will investigate how digoxin affects the binding of pyruvate kinase to pro-inflammatory loci and innate immune inflammatory responses in the peripheral blood.

Eligible Conditions
  • Inflammation

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~6 weeks
This trial's timeline: 3 weeks for screening, Varies for treatment, and 6 weeks for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Lower levels of spontaneous reactive oxygen species (ROS) production
Secondary outcome measures
Investigation of how human peripheral blood immune cells change their inflammatory responses after exposure to digoxin in vitro

Trial Design

3Treatment groups
Active Control
Placebo Group
Group I: Digoxin 3 mcg/Kg/dayActive Control1 Intervention
Patients receiving oral digoxin 3 mcg/Kg/day
Group II: Digoxin 0.15 mcgActive Control1 Intervention
Patients receiving oral digoxin 0.15 mcg/Kg/day
Group III: PlaceboPlacebo Group1 Intervention
oral placebo

Find a Location

Logistics

Participation is compensated

You will be compensated for participating in this trial.

Who is running the clinical trial?

National Institute on Alcohol Abuse and Alcoholism (NIAAA)NIH
799 Previous Clinical Trials
1,362,469 Total Patients Enrolled
6 Trials studying Inflammation
616 Patients Enrolled for Inflammation
Yale UniversityLead Sponsor
1,847 Previous Clinical Trials
2,736,486 Total Patients Enrolled
6 Trials studying Inflammation
205 Patients Enrolled for Inflammation
Wajahat Mehal, MDPrincipal InvestigatorYale University

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What therapeutic purpose is Digoxin 3 mcg/Kg/day prescribed for?

"Digoxin 3 mcg/Kg/day is an effective medicinal treatment for weaker myocardial contractility, mild-to-moderate heart failure, and cardiac arrhythmia."

Answered by AI

What is the magnitude of participants in this experiment?

"Affirmative. Based on the information available on clinicaltrials.gov, this research project is currently seeking participants for enrolment. Starting from March 1st 2021 and last updated July 11th 2022, 45 subjects need to be recruited at one site."

Answered by AI

Does this investigation accept applicants between the ages of 18-85?

"This trial is open to any individual of legal age (18+) and under the upper limit of 70 years old."

Answered by AI

Is the dose of Digoxin 3 mcg/Kg/day recognized by the FDA?

"The safety of Digoxin 3 mcg/Kg/day was rated a 1 due to the limited data associated with Phase 1 trials, which provide scant evidence regarding its efficacy and safety."

Answered by AI

Is this research endeavor currently enrolling participants?

"Clinicaltrials.gov reveals that this research is presently seeking participants, with the initial post being dated March 1st 2021 and the most recent update occurring July 11th 2022."

Answered by AI

What criteria must be met to become eligible for this clinical experiment?

"For this medical study, 45 individuals aged between 18 and 70 must be recruited that have an active inflammatory response. It is essential that proposed participants are of legal age or older."

Answered by AI

Has there been any prior research on the efficacy of administering Digoxin at a rate of 3 mcg/Kg/day?

"Currently, there are 9 active trials that focus on the efficacy of Digoxin 3 mcg/Kg/day with two in Phase 3. While most sites for this research are based in Nedlands, Western Australia; 85 different clinical locations across the world are doing research with Digoxin 3 mcg/Kg/day."

Answered by AI

Who else is applying?

What state do they live in?
South Carolina
What portion of applicants met pre-screening criteria?
Did not meet criteria
Recent research and studies
clinicaltrials.govStudy
Inhibition of Sterile Inflammation by Digoxin
2021. "Inhibition of Sterile Inflammation by Digoxin". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT03559868.
~10 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top